Navigation Links
OncoSec Receives ISO 13485 Quality Management System Certification
Date:7/30/2012

the OMS has been used in Europe in Phase IV clinical trials for the treatment of head and neck cancer and cutaneous and subcutaneous skin cancers.

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoSec Announces Issuance of New Patent for Method of Use
2. OncoSec Closes $7.75 Million Public Offering
3. OncoSec to Present at 10th Annual BioPartnering North America
4. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
5. UCSB assistant professor of physics receives US Presidential Science Award
6. First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
7. RIT professor receives National Science Foundation grant to improve on-chip networks with wireless technology
8. Little known pregnancy disease, Hyperemesis Gravidarum, receives awareness with a $20,000 donation from the H.E.R. Foundation to begin Genome Research at UCLA
9. Lupin Receives FDA Approval for Generic LYRICA(R)
10. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
11. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual ... monetization of intellectual property, announced today that the ... Uniden in the U.S. District Court for the ... has been rescheduled for November 10, 2014.  This ... The Court Order setting the Markman date was ...
(Date:10/1/2014)... 2014 As the world takes its first ... doubt that this century would mark the beginning of a ... medicine science. The fact that the world is experiencing a ... the scientific community. Almost half of these chronic conditions are ... prevented with medical care and intervention. While the world is ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 Today ... initial round of grants for the Brain Research ... that aims to develop and revolutionize new methods ... of the human brain. This first round of ... year 2014 was allocated to more than 100 ...
(Date:10/1/2014)... 30, 2014 New applications of structures ... have evolved in nature over millennia are featured in ... for applications in biophotonics in the October issue ... journal is published by SPIE, the international society for ... of the peer-reviewed articles are accessible via open access. ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3
... new microelectromechanical systems (MEMS) can benefit from a new ... and Technology (NIST) to measure a key mechanical property ... Youngs modulus of thin films not only for MEMS ... , Since 1727, scientists and engineers have used Youngs ...
... to high quality, fully annotated serum, tissue and blood ... available for Genomic ... Oncology Metrics, a,business that develops products and services ... Cureline Inc., a global,biosample management company dedicated to innovation ...
... 9 Novo Nordisk, a,healthcare company with an ... today announced the appointment of Alan C. Moses, ... is currently the,chief medical officer of Novo Nordisk ... the unique talent to integrate the science of ...
Cached Biology Technology:NIST develops test method for key micromechanical property 2Oncology Metrics and Cureline Announce Joint Marketing Agreement 2Oncology Metrics and Cureline Announce Joint Marketing Agreement 3Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide 2
(Date:9/30/2014)... to tetrachloroethylene (PCE) in drinking water may increase ... to a new study led by a Boston ... study, published in the journal Environmental Health ... pregnancies among 1,766 women in Cape Cod, Ma., ... to the early 1980s by the installation of ...
(Date:9/30/2014)... Fish can live in almost any aquatic environment on ... up many species are pushed to the limit. The ... could prove critical for how different species cope in ... the University of Gothenburg, published in the scientific journal ... Climate change continues apace thanks to increasing levels of ...
(Date:9/30/2014)... farm runoff in Hawaii is causing tumors in endangered ... study, published Tuesday in the peer-reviewed open-access journal ... up in algae that the turtles eat, promoting the ... internal organs. , Scientists at Duke University, the University ... (NOAA) conducted the study to better understand the causes ...
Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... world will gather March 20-22 at the University of ... change for global agriculture and recommend science-based actions to ... food, livelihood and sustainability. The Climate-Smart Agriculture Global ... builds on a 2011 international meeting on this theme ...
... SAN FRANCISCO Heart patients who can,t tolerate the ... option, according to a new study by researchers from ... Salt Lake City. Researchers found that pitavastatin, a ... attack, stroke and even death in up to 68 ...
... competition the Museum of Evolution at Uppsala University, Sweden, has ... Thunberg collection. The project will make the valuable plants available ... 350 years since Linnaeus,s disciple Carl Thunberg travelled with the ... Lanka and Java. In total he collected almost 28,000 plants ...
Cached Biology News:International conference to tackle climate-change threats to agriculture 2Researchers find alternative cholesterol-lowering drug for patients who can't tolerate statins 2Carl Thunberg's Japanese plants to be digitized 2
... Assay, 96 wells. ELISA.Specific for total ... MMP-3. No cross-reactivity with MMP-1, -2, -9. ... use with cell culture supernatant, serum, plasma ... to -30 C. Category: Drug Screening ...
... Dr. P Set from different human ... More organs maybe available upon request. ... items from the whole set, and ... price. All Dr. P Set ...
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Self Closing Forceps...
Biology Products: